| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 10.84 | 36033.3% |
| Total Income | 10.84 | 36033.3% |
| Expenditure | 19.91 | 10.1% |
| PBT | — | |
| Net Profit | -18.44 | 10.3% |
| OPM | -83.73% | |
| NPM | — | |
| EPS | -0.75 | 66.1% |
Precision BioSciences Reports Q1 2026 Financial Results
05 May 2026 · 5 May, 4:52 pm
Summary
Precision BioSciences reported financial results for the first quarter ended March 31, 2026. Total revenues for the quarter were $10.8 million, a significant increase compared to the previous year. Research and development expenses were $13.1 million, while general and administrative expenses amounted to $6.8 million. The company's cash balance as of March 31, 2026, was $125.8 million, expected to fund operations through 2028. Net loss for the quarter was $18.4 million, or $(0.75) per share.
Key Highlights
- 1
Precision BioSciences reported total revenues of $10.8 million for the quarter ended March 31, 2026, compared to less than $0.1 million for the quarter ended March 31, 2025.
- 2
The company's research and development expenses were $13.1 million for the quarter ended March 31, 2026.
- 3
General and administrative expenses were $6.8 million for the quarter ended March 31, 2026.
- 4
Precision BioSciences had approximately $125.8 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
- 5
Net loss was $18.4 million, or $(0.75) per share (basic and diluted), for the quarter ended March 31, 2026.
- 6
The company expects existing cash and cash equivalents will fund the Company’s cash runway through 2028.
Management Comments
Michael Amoroso
“During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the ELIMINATE-B trial and drove PBGENE-DMD through Investigational New Drug (IND) approval and activated our first clinical site as we prepare to dose the first patient in the FUNCTION-DMD trial.” “We remain focused on disciplined execution in 2026 as we generate additional clinical data from the ELIMINATE-B trial and enroll more sites and patients in the FUNCTION-DMD trial. We believe our ARCUS platform and targeted development strategy position us to deliver multiple important clinical and operational milestones this year.”
Informational and educational content only. Not investment advice.